Par Pharmaceutical in pre-emptive strike to protect Latuda generic

05-01-2017

Par Pharmaceutical in pre-emptive strike to protect Latuda generic

Tibor Duris / Shutterstock.com

Par Pharmaceutical has sought a declaratory judgment that it did not infringe patents belonging to Sumitomo and its subsidiary Sunovion that protect bipolar disorder drug Latuda (lurasidone hydrochloride).


patent, patent infringement, Par Pharmaceutical, Sunovion Pharmaceuticals, Sumitomo Dainippon Pharma, declaratory judgment, ANDA, generics

More on this story

Sumitomo sues over antipsychotic drug
14-02-2018

LSIPR